A multi-antigen vaccine in combination with an immunotoxin targeting tumor-associated fibroblast for treating murine melanoma

Molecular Therapy - Oncolytics

Volumn 3, Issue , 2016, Pages 16007-

  Fang, Jinxu ^a   Hu, Biliang ^a   Li, Si ^b   Zhang, Chupei ^a   Liu, Yarong ^a   Wang, Pin ^a,b  

^a University of Southern California   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; IMMUNOTOXIN; LENTIVIRUS VECTOR; MELANOMA ANTIGEN; MULTI ANTIGEN VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; FIBROBLAST; LYMPHOCYTIC INFILTRATION; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; STROMA; T LYMPHOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84969175036     PISSN: None     EISSN: 23727705     Source Type: Journal    
DOI: 10.1038/mto.2016.7     Document Type: Article

References (48)

1. Girardet, C, Ladisch, S, Heumann, D, Mach, JP and Carrel, S (1983). Identification by a monoclonal antibody of a glycolipid highly expressed by cells from the human myeloid lineage. Int J Cancer 32: 177-183.
2. Rosenberg, SA (1996). Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Natl Cancer Inst 88: 1635-1644.
3. Overwijk, WW, Tsung, A, Irvine, KR, Parkhurst, MR, Goletz, TJ, Tsung, K et al. (1998). gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 188: 277-286.
4. Xiang, R, Lode, HN, Chao, TH, Ruehlmann, JM, Dolman, CS, Rodriguez, F et al. (2000). An autologous oral DNA vaccine protects against murine melanoma. Proc Natl Acad Sci USA 97: 5492-5497.
5. Jaeger, E, Bernhard, H, Romero, P, Ringhoffer, M, Arand, M, Karbach, J et al. (1996). Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 66: 162-169.
6. Liu, Y, Peng, Y, Mi, M, Guevara-Patino, J, Munn, DH, Fu, N et al. (2009). Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice. J Immunol 182: 5960-5969.
7. Yang, HG, Hu, BL, Xiao, L and Wang, P (2011). Dendritic cell-directed lentivector vaccine induces antigen-specific immune responses against murine melanoma. Cancer Gene Ther 18: 370-380.
8. Rakhmilevich, AL, Imboden, M, Hao, Z, Macklin, MD, Roberts, T, Wright, KM et al. (2001). Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding Gp100 and granulocyte-macrophage colony-stimulating factor. Clin Cancer Res 7: 952-961.
9. Salgaller, ML, Marincola, FM, Cormier, JN and Rosenberg, SA (1996). Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 56: 4749-4757.
10. Mendiratta, SK, Thai, G, Eslahi, NK, Thull, NM, Matar, M, Bronte, V et al. (2001). Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2. Cancer Res 61: 859-863.
11. Rosenberg, SA, Yang, JC and Restifo, NP (2004). Cancer immunotherapy: moving beyond current vaccines. Nat Med 10: 909-915.
12. Curran, MA, Montalvo, W, Yagita, H and Allison, JP (2010). PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 107: 4275-4280.
13. Zitvogel, L, Tesniere, A, Apetoh, L, Ghiringhelli, F and Kroemer, G (2008). [Immunological aspects of anticancer chemotherapy]. Bull Acad Natl Med 192: 1469-87; discussion 1487.
14. Gulley, JL, Madan, RA and Arlen, PM (2007). Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine 25 Suppl 2: B89-B96.
15. Emens, LA and Jaffee, EM (2005). Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 65: 8059-8064.
16. Chu, Y, Wang, LX, Yang, G, Ross, HJ, Urba, WJ, Prell, R et al. (2006). Efficacy of GM-CSFproducing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma. J Immunother 29: 367-380.
17. Machiels, JP, Reilly, RT, Emens, LA, Ercolini, AM, Lei, RY, Weintraub, D et al. (2001). Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 61: 3689-3697.
18. Sierro, SR, Donda, A, Perret, R, Guillaume, P, Yagita, H, Levy, F et al. (2011). Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. Eur J Immunol 41: 2217-2228.
19. Hodi, FS, Butler, M, Oble, DA, Seiden, MV, Haluska, FG, Kruse, A et al. (2008). Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 105: 3005-3010.
20. Marx, J (2008). Cancer biology. All in the stroma: cancer's Cosa Nostra. Science 320: 38-41.
21. Loeffler, M, Kruger, JA, Niethammer, AG and Reisfeld, RA (2006). Targeting tumorassociated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 116: 1955-1962.
22. Bhowmick, NA, Neilson, EG and Moses, HL (2004). Stromal fibroblasts in cancer initiation and progression. Nature 432: 332-337.
23. Wang, XM, Yao, TW, Nadvi, NA, Osborne, B, McCaughan, GW and Gorrell, MD (2008). Fibroblast activation protein and chronic liver disease. Front Biosci 13: 3168-3180.
24. O'Brien, P and O'Connor, BF (2008). Seprase: An overview of an important matrix serine protease. Biochim Biophys Acta 1784: 1130-1145.
25. Kraman, M, Bambrough, PJ, Arnold, JN, Roberts, EW, Magiera, L, Jones, JO et al. (2010). Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 330: 827-830.
26. Kalluri, R and Zeisberg, M (2006). Fibroblasts in cancer. Nat Rev Cancer 6: 392-401.
27. Fang, J, Xiao, L, Joo, K-I, Liu, Y, Zhang, C, Liu, S et al. (2015). A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice. Int J Cancer 138: 1013-1023.
28. Gu-Trantien, C, Loi, S, Garaud, S, Equeter, C, Libin, M, de Wind, A et al. (2013). CD4+ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 123: 2873-2892.
29. Fridman, WH, Pages, F, Sautes-Fridman, C and Galon, J (2012). The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12: 298-306.
30. Brennen, WN, Isaacs, JT and Denmeade, SR (2012). Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther 11: 257-266.
31. Bui, JD, Uppaluri, R, Hsieh, CS and Schreiber, RD (2006). Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res 66: 7301-7309.
32. Bates, GJ, Fox, SB, Han, C, Leek, RD, Garcia, JF, Harris, AL et al. (2006). Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24: 5373-5380.
33. Mandl, SJ, Rountree, RB, Dalpozzo, K, Do, L, Lombardo, JR, Schoonmaker, PL et al. (2012). Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells. Cancer Immunol Immunother 61: 19-29.
34. Chen, J, Zhang, L, Wen, W, Hao, J, Zeng, P, Qian, X et al. (2012). Induction of HCA587-specific antitumor immunity with HCA587 protein formulated with CpG and ISCOM in mice. PLoS One 7: e47219.
35. Quezada, SA, Peggs, KS, Curran, MA and Allison, JP (2006). CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 116: 1935-1945.
36. Lindau, D, Gielen, P, Kroesen, M, Wesseling, P and Adema, GJ (2013). The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 138: 105-115.
37. Anees, M, Horak, P, El-Gazzar, A, Susani, M, Heinze, G, Perco, P et al. (2011). Recurrencefree survival in prostate cancer is related to increased stromal TRAIL expression. Cancer 117: 1172-1182.
38. Del Vecchio, M, Bajetta, E, Canova, S, Lotze, MT, Wesa, A, Parmiani, G et al. (2007). Interleukin-12: biological properties and clinical application. Clin Cancer Res 13: 4677-4685.
39. Fewell, JG, Matar, MM, Rice, JS, Brunhoeber, E, Slobodkin, G, Pence, C et al. (2009). Treatment of disseminated ovarian cancer using nonviral interleukin-12 gene therapy delivered intraperitoneally. J Gene Med 11: 718-728.
40. Jackaman, C, Bundell, CS, Kinnear, BF, Smith, AM, Filion, P, van Hagen, D et al. (2003). IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: A novel mechanism for IL-2. J Immunol 171: 5051-5063.
41. Ura, T, Okuda, K and Shimada, M (2014). Developments in Viral Vector-Based Vaccines. Vaccines (Basel) 2: 624-641.
42. Gajewski, TF, Woo, SR, Zha, Y, Spaapen, R, Zheng, Y, Corrales, L et al. (2013). Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol 25: 268-276.
43. Fotin-Mleczek, M, Zanzinger, K, Heidenreich, R, Lorenz, C, Kowalczyk, A, Kallen, KJ et al. (2014). mRNA-based vaccines synergize with radiation therapy to eradicate established tumors. Radiat Oncol 9: 180.
44. Pinchuk, IV, Saada, JI, Beswick, EJ, Boya, G, Qiu, SM, Mifflin, RC et al. (2008). PD-1 ligand expression by human colonic myofibroblasts/fibroblasts regulates CD4+ T-cell activity. Gastroenterology 135: 1228-1237, 1237.e1.
45. Nazareth, MR, Broderick, L, Simpson-Abelson, MR, Kelleher, RJ Jr, Yokota, SJ and Bankert, RB (2007). Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. J Immunol 178: 5552-5562.
46. Kakarla, S, Song, XT and Gottschalk, S (2012). Cancer-associated fibroblasts as targets for immunotherapy. Immunotherapy 4: 1129-1138.
47. Nizar, S, Meyer, B, Galustian, C, Kumar, D and Dalgleish, A (2010). T regulatory cells, the evolution of targeted immunotherapy. Biochim Biophys Acta 1806: 7-17.
48. Voron, T, Colussi, O, Marcheteau, E, Pernot, S, Nizard, M, Pointet, AL et al. (2015). VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med 212: 139-148.